[{"from": "human", "value": "Describe this molecule. [C][C][Branch2][Branch1][S][C][C][=C][Branch1][Branch2][C][=Branch1][C][=O][C][Ring1][#Branch1][C][=Branch2][Ring2][Branch2][=N][N][Ring1][Branch2][C][=C][C][=Branch1][=N][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][N][C][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][O][C][=Branch1][C][=O][C][N][C][Branch1][C][F][Branch1][C][F][F][C].[C][S][=Branch1][C][=O][=Branch1][C][=O][O]"}, {"from": "gpt", "value": "The molecule is the orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses."}]